OSI helps researchers write business plans, create pitches, recruit the board and set up a company. Investments from OSI span transition, seed and follow-on funding and range from £100,000 to £10M. OSI works with academics, Oxford University and entrepreneurs to create an ecosystem that supports the success of spinouts.
OSI is different from venture capitalists because it has a company structure rather than a fund structure which allows permanent capital and the patience needed to let investments mature. Spinouts may also have access to future capital.
OSI supported spinouts
Human Centric Drug Design
Oxford Semantic Technologies
Oxford Quantum Circuits
Orbit Discovery offers a DNA-encoded peptide display technology to identify potential peptide drugs for a range of chronic diseases.
Vaccitech is a T cell immunotherapy company developing products to treat and prevent infectious disease and cancer
An exosome therapeutics company founded in 2016 and based in Oxford, UK, that uses exosomes to deliver small and large molecule therapeutics. The company has a proprietary technology to modify exosomes to target specific organs such as the brain and central nervous system.
A biomedical company in United Kingdom that develops vaccines and vaccine development technology
Precision therapeutics company developing epigenetic therapies that target arginine methylation in cancer.
Metaboards uses metamaterials to embed wireless charging into surfaces so multiple items can be charged simultaneously.
Osler Diagnostics is a biosensor and medical device company.
A plant genetics company with technologies in crop protection that aims to help farmers produce healthy food from sustainable crop systems.
DiffBlue is an University of Oxford spin-out that is applying artificial intelligence to automated code synthesis.
Oxford Vacmedix UK Limited is an Oxford-based company founded in 2012 by Dr Shisong Jiang.